Why BioNTech’s CureVac Move Matters Far Beyond Vaccines

BioNTech’s all-share purchase of CureVac sharpens Europe’s focus on mRNA therapies beyond Covid-19

18 Jun 2025

Europe’s mRNA sector is undergoing a significant realignment after BioNTech agreed to acquire CureVac in an all-share deal valued at about $1.25bn, a move that companies and analysts say could speed the development of new cancer treatments.

The transaction, announced on June 12 and expected to close later in 2025, will be completed through an exchange of American Depositary Shares rather than cash. It brings together two of the region’s best-known mRNA groups, both of which rose to prominence during the Covid-19 pandemic.

BioNTech said the acquisition would strengthen its efforts to develop next-generation mRNA medicines, with a particular focus on oncology. CureVac will contribute research capabilities and manufacturing assets that BioNTech believes can shorten development timelines and improve efficiency.

A BioNTech spokesperson said the deal was “an important step” in delivering future mRNA therapies more quickly, reflecting growing competition in the field as companies look beyond vaccines and towards personalised cancer treatments.

For CureVac, the agreement offers stability after several years marked by clinical setbacks and a sharp fall in investor confidence. Analysts said becoming part of a larger group could help preserve the value of its technology at a time when funding for early-stage biotech companies has become harder to secure.

The deal also highlights broader pressures facing Europe’s biotechnology sector. As US-based rivals such as Moderna continue to scale up, European groups are under increasing pressure to consolidate, expand pipelines and show that mRNA technology can deliver commercially viable products outside infectious diseases.

Industry observers said the transaction underlines Europe’s ambition to remain competitive in emerging cancer therapies and personalised medicine, areas that are attracting growing interest from regulators and investors alike.

Some uncertainties remain. The companies must complete post-offer restructuring and integrate two research-driven organisations with different scientific cultures. Competition for patents, regulatory approvals and skilled researchers is also expected to intensify as the field matures.

Even so, analysts said the strategic logic of the deal was clear. With major players repositioning and capital becoming more selective, further partnerships and mergers are likely as companies race to turn mRNA science into approved treatments.